| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Histone-lysine N-methyltransferase EZH2;2.1.1.43;ENX-1;Enhancer of zeste homolog 2;Lysine N-methyltransferase 6;EZH2;KMT6; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human KMT6 / EZH2 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-EZH2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone IDF-5; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-KMT6 / EZH2 Rabbit Monoclonal Antibody catalog # M00050-1. Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: EZH2 (Histone-lysine N-methyltransferase EZH2).
- Antibody format: Monoclonal; clone IDF-5; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
EZH2 (protein: P2X purinoceptor 1) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys- 27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Compared to EZH2-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. . Reported cellular localization context: Nucleus . Tissue expression notes (as provided): Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis. .
Research relevance and current trends
- Research context keywords from the source record include: Cancer,2339,Chromatin Modifying Enzymes,Chromatin Remodeling,Epigenetics and Nuclear Signaling,Methylation,Tumor Biomarkers.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
Workflow ideas (metafield): Validate EZH2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect EZH2 expression by Western blot in cell or tissue lysates, Detect EZH2 in FFPE tissue sections by immunohistochemistry, Localize EZH2 by immunofluorescence/immunocytochemistry in cultured cells, Quantify EZH2-positive cells by flow cytometry in single-cell suspensions
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 45 kDa; calculated MW: 85363 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 45 kDa
- Cellular localization (provided): Nucleus .
- Tissue details (provided): Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
